RemedyRepack Inc. Initiates Class II Recall of Duloxetine Capsules Due to Nitrosamine Impurity and CGMP Deviations
RemedyRepack Inc. has initiated a nationwide Class II recall for Duloxetine Delayed-Release Capsules, 60 mg, due to N-nitroso-duloxetine impurity exceeding interim limits and Current Good Manufacturing Practice (CGMP) deviations. This event, following prior recalls, signals escalating compliance risks for procurement and regulatory affairs teams sourcing from RemedyRepack Inc.
FDA Mandates Class II Recall for RemedyRepack's Duloxetine Capsules Over Nitrosamine Contamination
RemedyRepack Inc. has initiated a Class II recall for specific lots of Duloxetine Delayed-Release Capsules, 60 mg, distributed nationwide across the United States. This critical action, designated recall number D-0165-2025, stems from significant Current Good Manufacturing Practice (CGMP) deviations identified at the company's Indiana, PA facility (postal code 15701-3571). More alarmingly, the recalled product was found to contain N-nitroso-duloxetine, a nitrosamine impurity, at levels exceeding the recommended interim limits established by the FDA. For procurement directors and regulatory affairs heads, this event signifies an immediate supply chain disruption and a heightened risk to patient safety due to the potential genotoxic nature of nitrosamines. The affected products include 1,564 blister cards (NDC 70518-0937-04, Lot # J0786744-061724, Exp. 06/30/2025) and 799 bottles (NDC 70518-0937-03, Lot # B3002625-060524, Exp. 10/31/2025). This voluntary, firm-initiated recall, first notified via letter on December 2, 2024, underscores the persistent challenges in maintaining stringent quality control throughout the pharmaceutical supply chain, particularly in repackaging operations. Businesses relying on RemedyRepack Inc. must immediately assess their exposure and consider the broader implications for product integrity and regulatory compliance.
RemedyRepack's Indiana, PA Facility: A Critical Repackaging Node Under Scrutiny
The recall originates from RemedyRepack Inc.'s operations in Indiana, Pennsylvania, a facility crucial for repackaging various pharmaceutical products. As a repackager, RemedyRepack Inc. takes finished drug products from original manufacturers, such as Rising Pharma, Inc. of Allendale, NJ (source NDC 57237-0019-99 for the recalled duloxetine), and re-labels or re-packages them into different configurations for distribution. This role places them as a vital intermediary in the pharmaceutical supply chain, meaning quality failures at this stage can impact products from multiple original manufacturers and reach a broad patient base. For supply chain VPs, this highlights the necessity of rigorous due diligence on all third-party service providers, including repackagers. The CGMP deviations cited in this recall indicate fundamental lapses in quality systems at the Indiana, PA site, which are essential for ensuring product identity, strength, quality, and purity. Any disruption at such a facility, especially one involving a widely prescribed medication like Duloxetine, can cascade through the distribution network, affecting pharmacies, hospitals, and ultimately, patient access. Business development executives must consider the reputational and operational risks associated with partners exhibiting such compliance deficiencies.
Supply Chain Exposure: Duloxetine Market Impact and Procurement Risks
The recall of Duloxetine Delayed-Release Capsules, 60 mg, directly impacts the supply chain for a medication widely used to treat major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. With distribution nationwide in the US, this Class II recall creates immediate pressure on procurement directors to secure alternative supplies and on regulatory affairs heads to manage potential patient and healthcare provider inquiries. While the specific quantities recalled—1,564 blister cards and 799 bottles—may seem modest, the broader implications of a nitrosamine impurity and CGMP deviations from a repackaging partner are significant. This event necessitates a rapid assessment of inventory levels for Duloxetine across all dosage forms and suppliers to prevent potential shortages. Furthermore, the incident underscores the vulnerability introduced when critical drug products pass through multiple hands in the supply chain. Companies relying on RemedyRepack Inc. for repackaging services of other molecules should initiate internal audits and risk assessments to identify potential exposure points. The commercial impact extends beyond the immediate product, potentially eroding trust in the repackaging sector and increasing scrutiny on all outsourced manufacturing and packaging operations.
Mitigating Risk: Strategic Sourcing and Qualification of Alternative Repackaging Partners
Given the critical nature of this recall and RemedyRepack Inc.'s recurring compliance issues, procurement teams must proactively identify and qualify alternative suppliers for both Duloxetine and general repackaging services. Our intelligence indicates no specific alternative suppliers for RemedyRepack Inc. or Duloxetine repackaging services are readily available in the ChemLifeIntel Knowledge Graph. This absence highlights a significant vulnerability for companies that may have concentrated their repackaging needs with a single vendor. Business development executives and supply chain VPs should prioritize diversifying their supplier base to mitigate future disruptions. Qualification timelines for new repackaging partners can be extensive, involving facility audits, quality system reviews, and regulatory approvals, often spanning several months. Therefore, immediate action is required to initiate these processes. Focusing on geographically diverse suppliers can further enhance resilience, reducing the impact of localized regulatory actions or operational failures. This strategic shift from single-source reliance to a multi-vendor approach is no longer merely a best practice but a commercial imperative to safeguard product supply, maintain regulatory compliance, and protect brand reputation in a volatile market.
RemedyRepack Inc.'s Escalating Regulatory History: A Pattern of Compliance Risk
This Class II recall of Duloxetine Delayed-Release Capsules marks a concerning pattern of recurring regulatory challenges for RemedyRepack Inc., signaling an escalating risk profile for any company engaging their services. This is the third Class II recall initiated by RemedyRepack Inc. within a single year. Previously, on May 15, 2024, the company faced a high-severity Class II recall for TraMADol HCl due to contamination issues, which carried implications often associated with a Warning Letter event. Just two months later, on July 24, 2024, RemedyRepack Inc. initiated another Class II recall for Potassium Chloride Capsules, which failed dissolution specifications. The current recall, involving CGMP deviations and a genotoxic nitrosamine impurity, further solidifies a trend of systemic quality control and manufacturing practice deficiencies at their Indiana, PA facility. For procurement directors, this history indicates that RemedyRepack Inc.'s quality management system may be fundamentally flawed, posing a continuous threat to the integrity of any product they handle. Regulatory affairs heads must recognize that continued engagement without demonstrable and sustained remediation efforts by RemedyRepack Inc. could lead to increased regulatory scrutiny on their own organizations, potential import alerts for products, and significant reputational damage. This pattern demands a critical re-evaluation of all existing and potential partnerships.
Remediation Timeline and Future Regulatory Enforcement Actions
The Class II recall of Duloxetine Delayed-Release Capsules by RemedyRepack Inc. is currently designated as 'Ongoing' by the FDA, indicating that the firm is actively managing the recall process, including product retrieval and notification. However, the presence of N-nitroso-duloxetine impurity and underlying CGMP deviations necessitates a comprehensive remediation effort that extends far beyond the immediate recall. RemedyRepack Inc. will be required to conduct a thorough root cause analysis, implement robust Corrective and Preventive Actions (CAPAs), and provide detailed evidence of these actions to the FDA. For business development executives, this means a period of intense regulatory scrutiny for RemedyRepack Inc., potentially leading to increased FDA inspections, further enforcement actions, or even an official FDA Warning Letter if the identified deficiencies are not adequately addressed. Supply chain VPs should anticipate potential delays or interruptions in future product flows from this facility, even for products not directly involved in this recall, as the company diverts resources to address these systemic issues. Companies sourcing from RemedyRepack Inc. should demand transparent communication regarding remediation progress, including access to audit reports and CAPA effectiveness checks. Failure to demonstrate sustainable compliance improvements could result in the FDA imposing more severe sanctions, impacting the broader pharmaceutical supply chain and necessitating rapid re-qualification of alternative repackaging partners.